期刊
BRITISH JOURNAL OF CANCER
卷 86, 期 9, 页码 1449-1456出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6600286
关键词
lung cancer; HER-2/neu; oncogene overexpression; immunohistochemistry; FISH; gene amplification
类别
资金
- NCI NIH HHS [U01-CA 85070, U01 CA085070, P50 CA058187, 2P30-CA 46934, P30 CA046934, P01-CA 58187] Funding Source: Medline
HER-2/neu gene amplification and cell surface overexpression are important factors in breast cancer for prognosis and prediction of sensitivity to anti-HER-2/neu monoclonal antibody therapy. In lung cancer, the clinical significance of HER-2/neu expression is currently under evaluation. We investigated 238 non-small lung carcinomas for HER-2/neu protein overexpression by immunchistochemistry using the HercepTest. We found 2+ or 3+ overexpression in 39 patients (16%), including 35%. in adenocarcinomas and 20% in large cell carcinomas, but only 1% of squamous cell carcinomas. Marked (3+) overexpression was uncommon (4%). The association between protein expression and gene copy number per cell, as determined by fluorescence in situ hybridisation assay, was Investigated in 5 1 of these NSCLC tumours. Twenty-seven tumours (53%) were negative by both tests. Marked (3+) protein expression and gene amplification were present in only 4% of samples. In 11 tumours (2156), gene gain was accompanied by chromosomal aneusomy and did not result in high protein levels while in 7 (14%) the score 2+ was associated with maximum number of signals per cell <9. The prognostic implication of HER-2/neu protein expression was studied in 187 surgically resected tumours. No statistical difference in survival was observed comparing patients with positive (2+/3+) and negative tumours (0/1+), although 3+ patients showed a tendency to shorter survival. The therapeutic implications of protein expression and gene amplification in lung cancer need to be examined in prospective clinical trials. (C) 2002 Cancer Research UK.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据